(Reuters) - Glaxo and three independent heart experts had sharply different views on what the results of the study meant.
The interim analysis of the study, funded by the drugmaker and published in the New England Journal of Medicine on Tuesday, was hastily published after another report last month suggested Avandia raised the risk considerably.
Read more at Reuters.com Business News
The interim analysis of the study, funded by the drugmaker and published in the New England Journal of Medicine on Tuesday, was hastily published after another report last month suggested Avandia raised the risk considerably.
Read more at Reuters.com Business News
No comments:
Post a Comment